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The impact of HIV on the prevalence of
asthma in Uganda: a general population
survey
Bruce J. Kirenga1* , Levicatus Mugenyi2, Corina de Jong3,4, J. Lucian Davis5, Winceslaus Katagira6,
Thys van der Molen3,4, Moses R. Kamya7 and Marike Boezen8
Abstract
Background: HIV and asthma are highly prevalent diseases in Africa but few studies have assessed the impact of
HIV on asthma prevalence in high HIV burden settings. The objective of this analysis was to compare the
prevalence of asthma among persons living with HIV (PLHIV) and those without HIV participating in the Uganda
National Asthma Survey (UNAS).
Methods: UNAS was a population-based survey of persons aged ≥12 years. Asthma was diagnosed based on
either self-reported current wheeze concurrently or within the prior 12 months; physician diagnosis; or use of
asthma medication. HIV was defined based on confidential self-report. We used Poisson regression with robust
standard errors to estimate asthma prevalence and the prevalence ratio (PR) for HIV and asthma.
Results: Of 3416 participants, 2067 (60.5%) knew their HIV status and 103 (5.0%) were PLHIV. Asthma
prevalence was 15.5% among PLHIV and 9.1% among those without HIV, PR 1.72, (95%CI 1.07–2.75, p = 0.025).
HIV modified the association of asthma with the following factors, PLHIV vs. not PLHIV: tobacco smoking (12% vs. 8%,
p = < 0.001), biomass use (11% vs. 7%, p = < 0.001), allergy (17% vs. 11%, p = < 0.001), family history of asthma
(17% vs. 11%, p = < 0.001), and prior TB treatment (15% vs. 10%, p = < 0.001).
Conclusion: In Uganda the prevalence of asthma is higher in PLHIV than in those without HIV, and HIV
interacts synergistically with other known asthma risk factors. Additional studies should explore the
mechanisms underlying these associations. Clinicians should consider asthma as a possible diagnosis in PLHIV
presenting with respiratory symptoms.
Keywords: Asthma, HIV, Prevalence, Uganda
Background
Human Immunodeficiency Virus (HIV) and asthma are
both highly prevalent diseases globally [1, 2]. An estimated
334 million people have asthma and 36.7 million people
have HIV [1, 2]. Both diseases disproportionately affect
Africa and other low and middle income countries
(LMICs) [2, 3]. The weighted mean prevalence of asthma
in Africa is 7.0% in the rural areas (2.5–11.5) and 9.6%
(3.9–15.2) in urban areas. The prevalence of asthma and
HIV in Uganda is 10% and 6.2% respectively [4, 5].
Epidemiological studies have found increased preva-
lence of asthma among HIV infected persons [6–13].
However, the number of studies is small and most are
either clinical or hospital based and most of them have
been conducted in high income low HIV burden set-
tings. Examples of available studies include a study that
included 248 HIV infected and 236 HIV uninfected
males. This study found that the prevalence of wheezing
was 54.4%, vs. 21.2%, p < 0.001 [9]. In another study
among 223 HIV patients in the USA, the prevalence of
doctor diagnosed asthma was 20.6 compared to 8.2% in
the general population [13]. In a study comparing 14,005
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HIV infected with age matched HIV uninfected controls
in Canada, the prevalence ratio for asthma was 1.31
(95% CI 1.20–1.43) [12].
Several mechanisms through which HIV increases the
prevalence of asthma have been proposed [14–16]. Not-
able among these is the HIV associated persistent immune
activation and inflammation [17]. It is also postulated that
HIV proteins such as the nef protein or activation of
memory CD4 T cells directly increase the risk of asthma
[18]. Studies indicate that the higher the viral loads, the
worse the lung function in HIV infected populations
[14, 17]. HIV infected persons have been found to have
higher levels of Immunoglobulin E (IgE) and this in-
creases with increasing immunosuppression [15]. IgE is
a well-known mediator of allergy and asthma. HIV could
also drive asthma through its association with predomin-
ance of T-helper 2 (Th2) pathway. Priming of the Th2
pathway is known to increase the risk of asthma and other
allergic diseases [19, 20]. In a cohort of 223 HIV infected
persons, doctor diagnosed asthma appeared to be more
common in participants with high sputum interleukin
4 (IL-4) (27% with asthma if high IL-4 vs.10.5% with
asthma if low IL-4, p = 0.02) [13]. Antiretroviral ther-
apy (ART) medications used to treat HIV have also
be implicated in increasing the risk of asthma among
HIV infected persons [21].
An interaction between HIV and asthma is important
in high HIV burden settings because with the availability
of highly active antiretroviral therapy and efficient health
systems to deliver them, many HIV infected people are
living longer into age groups where non-communicable
diseases (NCDs) are common. In addition, prevention of
HIV may lead to reduction in the burden of asthma.
Data on the burden of asthma in HIV may also lead to
assessment of asthma in HIV and routine HIV testing
among persons with asthma. Drug-drug interactions in
the management of patients with asthma-HIV comorbid-
ity is also a key consideration.
In this study we analyzed data from the Uganda national
asthma survey (UNAS) to determine if the prevalence of
asthma was higher among persons with self-reported HIV
infection. We also aimed to determine if HIV interacts
with other known asthma risk factors namely tobacco
smoking, biomass use, TB, family history of asthma and
allergy.
Methods
Design and study participants
UNAS was a cross sectional general population-based
survey conducted in Uganda in 2016. Participants were
selected in clusters (villages) selected by probability pro-
portionate to size by the Uganda Bureau of Statistics
using the Uganda National population and housing
census of 2014. Households (HHs) within clusters were
selected by simple random sampling from a HH list gener-
ated by village leaders. All persons aged ≥12 years who were
members of selected HH and provided written informed
consent (and assent in case of minors) were surveyed.
Exclusion criteria were: residing in congregate settings
(schools, prisons, homes) and temporary residents (less
than 2 weeks in household of selected villages).
Asthma diagnosis
Sampled participants were interviewed by trained research
assistants using a standardized questionnaire developed by
adapting questions from internationally recognized ques-
tionnaires, including the World Health Organization
(WHO) health survey [1, 22], the international study of
asthma and allergies in children (ISAAC) [22] and the
European community respiratory health survey (ECRHS)
surveys [23]. Asthma was defined as self-report of phys-
ician diagnosis, prescribed use of breathing medications
for asthma or report of a wheeze in the last 12 months.
HIV diagnosis
HIV status in this survey was established by self-report.
All participants were asked about their HIV status in
private interviews. Responses were either HIV positive,
HIV negative or unknown HIV status. HIV positive
participants were classified as persons living with HIV
(PLHIV).
Statistical analysis
Participants with unknown HIV status were excluded
from this analysis. Participants’ demographic and social
characteristics and known asthma risk factors (tobacco
smoking, allergy, family history of asthma, biomass use,
and history of TB treatment) were summarized as pro-
portions and compared between PLHIV and those who
were not using Chi-square and Fisher’s exact test statis-
tics as appropriate.
We used Poisson regression with robust standard
errors to estimate asthma prevalence and prevalence
ratios (PR) between PLHIV and those who were not
[24]. The Poisson model, an alternative for the
log-binomial, was used due to convergence problems
with the latter approach. The prevalence of asthma
and the corresponding PRs among patients with key
asthma risk factors namely tobacco smoking, biomass
smoke exposure, family history of asthma, tuberculosis
(TB) and allergy were also calculated. The PR ratio of
asthma between PLHIV and those who were not living
with HIV was then finally adjusted for these risk fac-
tors. Exposure to biomass smoke was defined as cook-
ing in the living space (same room where participants
slept), tobacco smoking was by self-report of being a
smoker while allergy was considered to be present if a
participant reported suffering in the past 12 months
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from any of the following: suffering in the past
12 months from any of watery itchy eyes, recurrent
skin rash, or having sneezing, nasal congestion or
rhinorrhea in the absence of an upper respiratory tract
infection). To assess for the interaction between HIV
and known asthma risk factors (tobacco smoking, bio-
mass use, history of TB treatment, allergy, family his-
tory), we calculated age-dependent asthma prevalence
comparing PLHIV and those who were not while keep-
ing all other factors at zero and then by each factor. A
graphical aid was used to visualize the age-dependent
asthma prevalence by these factors.
Results
Characteristics of study participants
Of 3416 UNAS participants, 2067 (60.5%) knew their HIV
status and 103 reported to be living with HIV (5.0% of the
group that knew their HIV status). The characteristics of
these participants by HIV status are shown in Table 1. The
proportions of participants with respiratory symptoms of
cough, sputum production and wheezing did not differ
by HIV status. However, the proportions with the
symptom breathlessness differed significantly by HIV
status, positive vs. negative (17.5% vs. 9.0%, p = 0.004).
Tobacco smoking was higher among PLHIV (12.6% vs.
7.9%, p = 0.086) as well as having history of TB treat-
ment (9.7% vs.1.5%, p < 0.001).
Prevalence of asthma by HIV status
The prevalence of asthma among PLHIV was 15.5%
while that among those without HIV was 9.1%, PR 1.72
(95% CI: 1.07–2.75, p = 0.025). After adjusting for gen-
der, age, tobacco smoking, biomass exposure, TB treat-
ment, family history of asthma and allergy, the PR ratio
decreased to 1.54 (95% CI: 0.94–2.51, p = 0.085), Table 2.
A high prevalence of asthma among PLHIV was main-
tained at all ages irrespective of absence or presence of
other risk factors of tobacco smoking, biomass use, al-
lergy, family history of asthma and previous TB treat-
ment (Fig. 1). Considering only participants younger
than 35 years the prevalence of asthma was still higher
among PLHIV, PR 3.06 (Fig. 2). The prevalence of asthma
among participants with known HIV status and un-
known HIV status did not differ significantly (9.4%
vs.9.0%, p = 0.689), Table 3. HIV modified the associ-
ation between asthma and other asthma risk factors, posi-
tive vs. negative: tobacco smoking (12% vs.8%, p = <
0.001) biomass use (11% vs. 7%, p = < 0.001), allergy
(17% vs. 11%, p = < 0.001), family history asthma (17%
vs. 11%, p = < 0.001) and TB treatment (15% vs. 10%,
p = < 0.001), Fig. 3.
Prevalence of asthma by other factors
Other factors associated with increased prevalence of
asthma in this study were biomass use adjusted PR 1.56
(95% CI: 1.18–2.07, p = 0.002), tobacco smoking 1.79
(95% CI: 1.23–2.60, p = 0.002), history of TB treatment
2.20 (95% CI: 1.26–3.84, p = 0.005), family history of
asthma 2.41 (95% CI: 1.81–3.23, p = < 0.001), and allergy
2.45 (95% CI: 1.85–3.26, p = < 0.001), Table 2.
Discussion
This study has established that the prevalence of
asthma among PLHIV is higher than among those
without HIV and that HIV modifies the associations
of asthma with tobacco smoking, biomass use, TB, al-
lergy and family history of asthma. The study also
shows that the only respiratory symptom more preva-
lent in PLHIV than without PLHIV is breathlessness.
In terms of asthma risk factors the study found that
PLHIV have high rates of tobacco smoking and his-
tory of TB treatment.
A higher prevalence of asthma among PLHIV has
been reported in previous studies in clinic-based stud-
ies in high income with low HIV prevalence [6–12]. In
248 HIV infected and 236 HIV uninfected males, the
prevalence of wheezing was 54.4%, vs. 21.2%, p < 0.001








Male gender, n(%) 31 (30.1) 763 (38.8) 0.076
Age groups n(%) < 0.001
< 15 1 (1.0) 91 (4.6)
15–24 10 (9.7) 474 (24.1)
25–34 27 (26.2) 510 (25.9)
35–44 33 (32.0) 388 (19.7)
45–54 27 (26.2) 304 (15.5)
55–64 4 (3.9) 131 (6.7)
65+ 1 (1.0) 68 (3.5)
Respiratory Symptoms n(%)
Cough 23 (22.3) 404 (20.6) 0.665
Sputum 7 (6.8) 140 (7.1) 0.900
Wheezing 11 (10.7) 131 (6.7) 0.116
Shortness of breath 18 (17.5) 177 (9.0) 0.004
Risk factors and co-morbid conditions n (%)
History of smoking 13 (12.6) 155 (7.9) 0.086
Exposure to bio-mass 24 (23.3) 385 (19.6) 0.357
Ever been treated for TB 10 (9.7) 30 (1.5) < 0.001
Allergy 42 (40.8) 721 (36.7) 0.400
Family history of asthma 15 (14.6) 220 (11.2) 0.295
PLHIV people living with HIV, TB tuberculosis
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[9] while in a study comparing 14,005 HIV infected
patients with age matched HIV uninfected controls in
Canada, the PR for asthma was 1.31 (95% CI 1.20–
1.43) [12]. In another study among 223 HIV patients
in the USA, the prevalence of doctor diagnosed
asthma was 20.6 compared to 8.2% in the general
population [13]. Although after adjusting for other
risk factors of asthma such as smoking, biomass
smoke, TB, allergy the PR ratio for asthma in PLHIV
reduced to 1.54 with a trend p-value of 0.085. The re-
sults are however line with the findings from the stud-
ies above which increases the possibility that HIV is
associated with asthma even in the present study.
We investigated the effect HIV had on the risk of
asthma from other asthma risk factors. We found that
PLHIV had higher rates of smoking as previously
reported [25, 26]. The prevalence of asthma among
tobacco smoking PLHIV was 12.6% compared to 7.9%
of smokers who were not living with HIV. The find-
ing of high smoking rates among PLHIV in this study
has been reported in previous studies [25, 26]. This
finding therefore calls for heightened efforts to reduce
smoking among PLHIV.”
We compared respiratory symptoms between HIV
infected and HIV uninfected participants and found
that there were no differences except for breathless-
ness. George et al. found that HIV infected persons
had high rates of most respiratory symptoms [21]. We
cannot explain why we failed to observe these differ-
ences in respiratory symptoms apart from breathless-
ness. The excess breathlessness in the HIV infected
participants might be due to interstitial and diffusion
derangements that are so prevalent among HIV infected
persons [27–29]. Gingo et al. in a cross-sectional analysis
Table 2 Asthma prevalence by HIV and potential confounding factors
n (%) Prevalence of asthma % Crude PR (95% CI) p Adjusted PRb (95% CI) p-value
Characteristic
HIV status
Infected 103 (5.0) 15.5 1.72 (1.07–2.75) 0.025 1.54 (0.94–2.51) 0.085
Uninfected 1966 (95.0) 9.1 Reference Reference
Gender
Female 1275 (61.6) 9.9 1.15 (0.87–1.53) 0.319 1.24 (0.92–1.68) 0.159
Male 794 (38.4) 8.6 Reference Reference
Smoking
Yes 168 (8.1) 16.7 1.91 (1.32–2.76) 0.001 1.79 (1.23–2.60) 0.002
No 1901 (91.9) 8.7 Reference Reference
Biomass use
Yes 409 (19.8) 14.2 1.74 (1.31–2.32) < 0.001 1.56 (1.18–2.07) 0.002
No 1659 (80.2) 8.1 Reference Reference
TB treatment
Yes 40 (1.9) 22.5 2.46 (1.36–4.45) 0.003 2.20 (1.26–3.84) 0.005
No 2026 (98.1) 9.1 Reference Reference
Family history of asthma
Yes 235 (11.4) 23.8 3.16 (2.39–4.18) < 0.001 2.41 (1.81–3.23) < 0.001
No 1832 (88.6) 7.5 Reference Reference
Allergy
Yes 763 (36.9) 16.0 2.90 (2.20–3.83) < 0.001 2.45 (1.85–3.26) < 0.001
No 1306 (63.1) 5.5 Reference Reference
TB/HIV (HIV infected and history of TB treatment)
Yes 10 (0.5) 10.0 1.07 (0.17–6.89) 0.946 0.20 (0.02–1.66) 0.135
No 2059 (99.5) 9.4 Reference Reference
Age in yearsa 2.09 (1.52–2.88) < 0.001 1.83 (1.30–2.58) 0.001
alog transformed due to skewness, bAdjusted for age, gender, smoking, biomass smoke exposure, allergy, history of TB and family history of asthma, CI confidence
interval, TB tuberculosis, PR prevalence ratio
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of 158 HIV-infected individuals without acute respiratory
symptoms or infection found that 55 (34.8%) participants
had a significantly reduced DLCO (< 60% predicted) [29].
This study had limitations. Most notably the use of
self-report to determine HIV infection. Self-report as a
means of determining HIV status has been reported to have
low sensitivity but high specificity [30, 31]. Among older
adults (≥40 years) in South Africa, Rohr et al. report a sen-
sitivity of HIV self-report of 51.2% (95% CI: 48.2–54.3) and
specificity was 99.0% (95% CI: 98.7–99.4) [30, 31]. The low
sensitivity of self-report may also be present in our study,
the self-reported prevalence of HIV in our survey is 3.1%,
Fig. 1 Prevalence of asthma by age stratified by HIV status and other asthma risk factors: a Prevalence of asthma by age and HIV status keeping
all other factors at zero. b Prevalence of asthma by age and HIV status among participants exposed to biomass smoke (c) Prevalence of asthma
by age and HIV status among smokers. d Prevalence of asthma by age and HIV status among participants with history of allergy. e Prevalence of
asthma by age and HIV status among participants with family history of asthma f) Prevalence of asthma by age and HIV status among
participants with history of TB treatment
Fig. 2 Asthma prevalence ratios (HIV+ vs HIV-) considering different ages of participants
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which is much lower than the national prevalence of 6.2%
[4]. We believe that differential classification of HIV by
asthma status is unlikely, but if present would likely tend to
underestimate the prevalence ratio if patients without HIV
are less likely to report HIV status. We performed further
analysis on our data comparing demographic characteristics
and asthma prevalence between participants with known
HIV status and those with unknown HIV status, Table 3. As
can be seen in this table the prevalence of asthma among
these two groups did not significantly differ.
Another limitation of our study is that asthma was
diagnosed based on history or current wheeze, prior
physician diagnosis and being currently on asthma medi-
cations. However the methods used in this study are the
standard methods that are used in most asthma sur-
veys including the ISAAC), ECRHS)and the WHO
health survey [1, 22, 23]. We recognise that wheez-
ing could be due to other diseases such as chronic
obstructive pulmonary disease (COPD). Therefore, it
is possible that some of the participants classified as
asthma could have had COPD which is also known
to be associated with HIV. We performed sensitivity
analysis considering only participants who are youn-
ger than 35 years, the age below which the diagnosis
of COPD is unlikely and found that the prevalence
of asthma in age group was still higher among the
HIV infected participants (Fig. 1 left panel) implying
that the association between asthma and HIV in this
study might be a true one. There are however other
conditions that can cause wheezing such as bronchi-
ectasis, heart failure and mechanical airway obstruc-
tion [32, 33] that we could not exclude although
these conditions are deemed to be rare.
Despite the limitations, our findings have several
scientific, healthcare and programmatic implications.
Firstly, HIV care programs need to build capacity for
diagnosis of asthma and its management. At the
same time there may be need to test for HIV among
asthma patients in high HIV burden settings and to
know their ART status and the medications they are
taking. Asthma and HIV co-morbidity can be associ-
ated with complexities that can arise while managing
the two diseases notably drug-drug interactions and
increased rates of adverse events as can occur with
Table 3 Participants characteristics by HIV status (known vs. unknown status)
HIV status known (N = 2069) HIV status unknown (N = 1347) P-value
Characteristic
Male gender 794 (38.4) 533 (39.6) 0.484
Age groups < 0.001
< 15 92 (4.5) 280 (20.8)
15–24 484 (23.4) 400 (29.7)
25–34 537 (26.0) 144 (10.7)
35–44 421 (20.4) 156 (11.6)
45–54 331 (16.0) 144 (10.7)
55–64 135 (6.5) 90 (6.7)
65+ 69 (3.3) 133 (9.9)
Respiratory Symptoms
Cough 427 (20.7) 284 (21.1) 0.751
Sputum 147 (7.1) 110 (8.2) 0.250
Wheezing 142 (6.9) 84 (6.2) 0.471
Shortness of breath 195 (9.4) 114 (8.5) 0.337
Risk factors and co-morbid conditions
History of smoking 168 (8.1) 74 (5.5) 0.004
Exposure to bio-mass 409 (19.8) 289 (21.5) 0.235
Ever been treated for TB 40 (1.9) 10 (0.7) 0.005
Allergy 763 (36.9) 433 (32.2) 0.005
Family history of asthma 235 (11.4) 142 (10.6) 0.455
Asthma
Positive 194 (9.4) 121 (9.0) 0.698
TB tuberculosis
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corticosteroids used in the management of asthma.
Corticosteroids use in HIV infected persons has been
associated with adverse outcomes such as the devel-
opment of cancers like Kaposi’s sarcoma and TB
[34–36]. Another key drug-drug interaction to con-
sider is that between protease inhibitors and cortico-
steroids, which is mediated through the effects of
PIs on the cytochrome CYP450 3A4 drug metabol-
ism pathway [37, 38]. This interaction can lead to
complications such as Cushing’s syndrome, hyperten-
sion and poor CD4 cell count recovery [38]. We
found that HIV modified the risk of asthma from
other risk factors. This calls for vigorous prevention
of these risk factors among PLHIV. PLHIV in this
study had higher rates of tobacco smoking. This calls
for heightened efforts to reduce smoking among
PLHIV since they may be more likely to develop to-
bacco associated lung diseases. In terms of science,
our findings call for more research on the impact of
HIV on asthma in high HIV burden settings and the
mechanistic pathways of the HIV asthma interaction
especially in settings with high rates of factors like
TB and biomass smoke exposure. The impact of
HIV on asthma prognosis also needs to be studied.
Conclusion
In conclusion, the prevalence of asthma among PLHIV
in this survey is higher than among those without HIV.
HIV also modifies the risk of asthma from other asthma
risk factors such as tobacco smoking, TB, exposure to
biomass, allergy and family history of asthma. PLHIV
should be assessed for asthma and asthma patients
should undergo HIV testing.
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